Oncology Frontier FM · ESMO BC Special | Professor Heather Parsons: ctDNA Monitoring for Predicting Recurrence in ER-Positive Early Breast Cancer—Promising Potential, but Evidence Still Needed

Oncology Frontier FM · ESMO BC Special | Professor Heather Parsons: ctDNA Monitoring for Predicting Recurrence in ER-Positive Early Breast Cancer—Promising Potential, but Evidence Still Needed

Liquid biopsy technologies are rapidly advancing, and circulating tumor DNA (ctDNA) monitoring has demonstrated enormous potential in precision treatment for breast cancer. During the Educational Session “Adjuvant Therapy for ER-Positive Breast Cancer” at the ESMO Breast Cancer Congress (ESMO BC), Professor Heather Parsons from the Fred Hutchinson Cancer Center delivered a presentation entitled “The Role of ctDNA Monitoring in ER+ Early Breast Cancer: Could It Change Practice?”
Where Is the Next Breakthrough in Colorectal Cancer? Prof. Toh Han Chong Shares His Insights

Where Is the Next Breakthrough in Colorectal Cancer? Prof. Toh Han Chong Shares His Insights

On March 21, 2026, the Academic Seminar on Clinical Practices of Colorectal Surgery was held in Hangzhou, Zhejiang Province. Hosted by the Second Affiliated Hospital of Zhejiang University School of Medicine, the event brought together top-tier colorectal surgery experts from across China for in-depth discussions on key topics, including colorectal cancer liver metastasis, peritoneal metastasis, para-aortic lymph node metastasis, locally advanced rectal cancer, combined organ resection, and the association between obesity and colorectal cancer. Prof. Toh Han Chong from the National Cancer Centre Singapore (NCCS) attended the conference.
PI Insights S01E02 | Where Are the Boundaries of Bladder Preservation? — The Clinical Rationale and Technical Foundation Behind the Expanded Enrollment Criteria of HOPE-02/03

PI Insights S01E02 | Where Are the Boundaries of Bladder Preservation? — The Clinical Rationale and Technical Foundation Behind the Expanded Enrollment Criteria of HOPE-02/03

In the previous episode, we reviewed the full evolution of the HOPE series from HOPE-01 through HOPE-04. Among all its design features, one detail may represent the most distinctive — and perhaps boldest — aspect of the HOPE program within the global bladder-preservation landscape: its enrollment criteria.
PI Perspectives S01E03 | Finding Balance in the Chemo-Immunotherapy Era — A Strategic Dialogue Between HOPE-02, NIAGARA, RETAIN-02, and INDI-BLADE

PI Perspectives S01E03 | Finding Balance in the Chemo-Immunotherapy Era — A Strategic Dialogue Between HOPE-02, NIAGARA, RETAIN-02, and INDI-BLADE

In the previous episode, we explored the clinical rationale and technical safeguards behind the expanded enrollment criteria of HOPE-02/03. In this installment, we place HOPE-02 within the broader landscape of perioperative and bladder-preservation research in muscle-invasive bladder cancer (MIBC) to better understand its position among contemporary global studies.
Cancer Communications | Professor Shi Yanxia and Professor An Xin’s Team Explores a New Post-Resistance Treatment Strategy for Advanced Urothelial Carcinoma

Cancer Communications | Professor Shi Yanxia and Professor An Xin’s Team Explores a New Post-Resistance Treatment Strategy for Advanced Urothelial Carcinoma

On April 21, 2026, Professor Shi Yanxia and Professor An Xin’s team from Sun Yat-sen University Cancer Center published their latest findings in the international journal Cancer Communications under the title “Camrelizumab Plus Nab-paclitaxel in Patients with Previously Treated Advanced Urothelial Carcinoma: A Multicenter Phase II Study.”
CUDA Yanqi Lake Conference | Professor Xiaodong Wen : From Evidence to Practice — How Real-World Precision Therapy Addresses Clinical Challenges in Urologic Oncology

CUDA Yanqi Lake Conference | Professor Xiaodong Wen : From Evidence to Practice — How Real-World Precision Therapy Addresses Clinical Challenges in Urologic Oncology

Randomized controlled trials (RCTs), regarded as the “gold standard” of evidence-based medicine, serve as the cornerstone for establishing oncology treatment guidelines. However, it is equally important to recognize that the strict inclusion and exclusion criteria of RCTs often create a significant gap between trial populations and the realities of everyday clinical practice, where many patients are elderly, have multiple comorbidities, or have experienced failure of several prior treatment lines.
“Deep Dive Debate” | After Achieving pCR with Immunotherapy in TNBC, Should Adjuvant Immunotherapy Be Continued or Stopped?

“Deep Dive Debate” | After Achieving pCR with Immunotherapy in TNBC, Should Adjuvant Immunotherapy Be Continued or Stopped?

With the success of landmark clinical studies such as KEYNOTE-522, neoadjuvant treatment for early-stage triple-negative breast cancer (TNBC) has fully entered the era of immunotherapy combined with chemotherapy. While this strategy has significantly improved pathological complete response (pCR) rates and delivered substantial survival benefits, it has also raised one of the most debated questions in current clinical practice:
2026 CSCO BC Guideline Highlights | Professor Jiayi Chen: Key Updates in Breast Cancer Radiotherapy

2026 CSCO BC Guideline Highlights | Professor Jiayi Chen: Key Updates in Breast Cancer Radiotherapy

The 2026 National Breast Cancer Conference was held in Beijing from April 10–12, during which major updates to the Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2026 (CSCO BC Guidelines 2026) were officially released. At the meeting, Professor Jiayi Chen from Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, reviewed and interpreted the latest updates in the radiotherapy section of the guidelines.